Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

• المؤلفون الرئيسيون: Cohen C., Molina J., Cahn P., Clotet B., Fourie J., Grinsztejn B., Wu H., Johnson M., Saag M., Supparatpinyo K., Crauwels H., Lefebvre E., Rimsky L., Vanveggel S., Williams P., Boven K.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862777419&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42848

Background: Pooled analysis of phase 3, double-blind, doubledummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoprox...